Document is current
Any future updates will be listed below
-
Authors
Karam, Chafic
Moffit, Colleen https://orcid.org/0009-0001-5561-9738
Summers, Catherine
Merkel, Madeline P.
Kochman, Fran M.
Weijers, Laure
Puls, Mathilde
Schurer, Marieke
Jones, Emily
Mason, Nicola
Finkel, Muriel
Schmitt, Paula
Hanna, Mazen
-
Funding
Funding for this research was provided by:
Alnylam Pharmaceuticals
- License Information
-
More Information
Article History
Received: 10 October 2023
Accepted: 13 October 2024
First Online: 8 November 2024
Declarations
:
: Consent to participate was obtained through an introductory question contained in the survey and via verbal agreement prior to the interviews. The Western Copernicus Group Institutional Review Board approved both phases of the study (reference number: 1297323).
: This was obtained via the survey and interviews.
: CK has received honoraria for consulting for Takeda, Argenx, AstraZeneca, Sanofi, UCB, Alexion, Ionis, Neuroderm, Corino, and Alnylam. He has received research funding from Ionis and AstraZeneca. CM, CS, MPM and FMK are employees and stockholders of Alnylam Pharmaceuticals, Inc. LW, MP, MS, EJ and NM work on research studies contracted between their employer, Lumanity, and pharmaceutical company sponsors. As salaried employees, their compensation is not connected to the projects they work on. PS and MF are consultants on the Alnylam TTR Patient Advocacy Leadership Advisory Council and have not received any compensation or other type of funding specific to their involvement in the study reported here. MH has served on advisory boards for Pfizer, Alnylam, Eidos, Ionis, and Alexion Pharmaceuticals.No other disclosures were reported.
